News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Caissa Capital Management ltd.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/29/2023 |
SC 13G/A
| Caissa Capital Management ltd. reports a 0% stake in Avalo Therapeutics, Inc. |
| 06/09/2023 |
4
| Caissa Capital Management ltd. (10% Owner) has filed a Form 4 on Avalo Therapeutics, Inc.|
Txns:
| Bought 2,984 shares
@ $3.4914, valued at
$10.4k
Bought 6,398 shares
@ $3.9271, valued at
$25.1k
Bought 5,044 shares
@ $4.1427, valued at
$20.9k
|
|
| 06/02/2023 |
4
| Caissa Capital Management ltd. (10% Owner) has filed a Form 4 on Avalo Therapeutics, Inc.|
Txns:
| Bought 844 shares
@ $2.87, valued at
$2.4k
|
|
| 05/30/2023 |
4
| Caissa Capital Management ltd. (10% Owner) has filed a Form 4 on Avalo Therapeutics, Inc.|
Txns:
| Bought 2,000 shares
@ $2.77, valued at
$5.5k
Bought 671 shares
@ $2.867, valued at
$1.9k
|
|
| 05/24/2023 |
4
| Caissa Capital Management ltd. (10% Owner) has filed a Form 4 on Avalo Therapeutics, Inc.|
Txns:
| Bought 3,481 shares
@ $3.0072, valued at
$10.5k
Bought 5,519 shares
@ $2.9622, valued at
$16.3k
|
|
| 05/16/2023 |
4
| Caissa Capital Management ltd. (10% Owner) has filed a Form 4 on Avalo Therapeutics, Inc.|
Txns:
| Bought 2,285 shares
@ $2.45, valued at
$5.6k
Bought 1,715 shares
@ $2.5459, valued at
$4.4k
Bought 379 shares
@ $2.75, valued at
$1k
|
|
| 05/08/2023 |
4
| Caissa Capital Management ltd. (10% Owner) has filed a Form 4 on Avalo Therapeutics, Inc.|
Txns:
| Bought 15,000 shares
@ $2.7921, valued at
$41.9k
Bought 5,000 shares
@ $2.875, valued at
$14.4k
Bought 5,000 shares
@ $2.6216, valued at
$13.1k
|
|
| 04/27/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 04/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/14/2023 |
SC 13G/A
| Caissa Capital Management ltd. reports a 10.6% stake in Avalo Therapeutics, Inc. |
| 08/08/2022 |
SC 13G/A
| Caissa Capital Management ltd. reports a 10.4% stake in Avalo Therapeutics, Inc. |
| 05/17/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
|
|